Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: Eight years on

118Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.

Abstract

Insulin-like growth factor (IGF)-I, and its main binding protein, IGFBP-3, are multi-functional regulatory peptides of cell growth and survival, attributes important for tumourigenesis. Following seminal work published in 1998, it has been hypothesised that circulating concentrations of these growth factors may be associated with cancer risk. Systematic reviews have reported that high normal range circulating levels of total IGF-I predict for pre- but not post-menopausal breast cancer. By contrast, associations with circulating IGFBP-3 have been inconsistent. A cumulative meta-analysis demonstrates that earlier reported positive associations between IGFBP-3 and pre-menopausal breast cancer risk now seem less clear as large-size cohorts are published. The reasons are complex and include differences in study design, lack of standardisation between assays, and variations in IGFBP-3 proteolytic activity - these are discussed in this commentary. © 2006 Society for Endocrinology.

Cite

CITATION STYLE

APA

Renehan, A. G., Harvie, M., & Howell, A. (2006, June). Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: Eight years on. Endocrine-Related Cancer. https://doi.org/10.1677/erc.1.01219

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free